NFI releases its Sustainability Report for 2024

NFI releases its Sustainability Report for 2024 GlobeNewswire August 12, 2025 WINNIPEG, Manitoba, Aug. 12, 2025 (GLOBE NEWSWIRE) — (TSX: NFI, OTC: NFYEF, TSX: NFI.DB) NFI Group Inc. (NFI, or the Company) a recognized leader in propulsion-agnostic bus and coach mobility solutions, today released its Sustainability Report for 2024 (the Sustainability Report, or Report), which […]

American Oncology Network Reports Strong Growth and Record Milestones in 2025

American Oncology Network Reports Strong Growth and Record Milestones in 2025 Annual revenue surpasses $2 billion for the 12 months ended June 30, 2025, reflecting >40% growth over the prior 12-month period. Provider network grows to >300 across 20 states. New treatment innovations broaden access to cutting-edge cancer care GlobeNewswire August 12, 2025 FORT MYERS,

Counslr Launches in Schools Across the Country to Increase Mental Health Care Access

Counslr Launches in Schools Across the Country to Increase Mental Health Care Access Need For Alternative Models Grows in School Communities as Budget Cuts Reduce Student Mental Health Support GlobeNewswire August 12, 2025 NEW YORK, Aug. 12, 2025 (GLOBE NEWSWIRE) — Counslr, a leading mental health and wellness platform, announced today that it has expanded

Core Molding Technologies to Present and Host 1×1 Meetings at the 16th Annual Midwest IDEAS Investor Conference on August 26, 2025

Core Molding Technologies to Present and Host 1×1 Meetings at the 16th Annual Midwest IDEAS Investor Conference on August 26, 2025 GlobeNewswire August 12, 2025 COLUMBUS, Ohio, Aug. 12, 2025 (GLOBE NEWSWIRE) — Core Molding Technologies, Inc. (NYSE American: CMT) (“Core Molding,” “Core” or the “Company”), a leading engineered materials company specializing in molded structural

Elicio Therapeutics Announces Publication of ELI-002 Updated AMPLIFY-201 Phase 1 Follow-up Data in Nature Medicine for Minimal Residual Disease (“MRD”) Positive, Adjuvant-Stage Patients

Elicio Therapeutics Announces Publication of ELI-002 Updated AMPLIFY-201 Phase 1 Follow-up Data in Nature Medicine for Minimal Residual Disease (“MRD”) Positive, Adjuvant-Stage Patients GlobeNewswire August 12, 2025 At extended median follow-up of 19.7 months, median overall survival (“OS”) increased from 16.33 to 28.94 months Clinical efficacy correlated with the magnitude of T cell responses specific

SimpleTherapy Ranks No. 1234 on the 2025 Inc. 5000 List of America’s Fastest-Growing Private Companies

SimpleTherapy Ranks No. 1234 on the 2025 Inc. 5000 List of America's Fastest-Growing Private Companies Debuts at No. 3 among Fresno-based companies and No. 127 in Healthcare & Medical GlobeNewswire August 12, 2025 FRESNO, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) — SimpleTherapy, a leading omnichannel care provider of musculoskeletal (MSK) and behavioral health care solutions,

57 Confluent Health Physical and Occupational Therapists Receive Board-Certified Clinical Specialist Credential

57 Confluent Health Physical and Occupational Therapists Receive Board-Certified Clinical Specialist Credential Certification Reflects Highest Level of Advanced Clinical Practice in Musculoskeletal Care GlobeNewswire August 12, 2025 LOUISVILLE, Ky., Aug. 12, 2025 (GLOBE NEWSWIRE) — Fifty-seven Physical and Occupational Therapists from Confluent Health's Partner Brands have achieved nationally recognized board certifications, a prestigious milestone that

Silexion Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Silexion Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update Continued advancement of SIL204 preclinical program with strong efficacy data across multiple KRAS-driven cancer types; company strengthened financial position and maintains progress toward clinical trials GlobeNewswire August 12, 2025 GRAND CAYMAN, Cayman Islands, Aug. 12, 2025 (GLOBE NEWSWIRE) — Silexion Therapeutics Corp. (NASDAQ:

ProPhase Labs Announces Full USPTO Approval for Issuance of U.S. Patent Protecting Esophageal Adenocarcinoma Risk Assessment

ProPhase Labs Announces Full USPTO Approval for Issuance of U.S. Patent Protecting Esophageal Adenocarcinoma Risk Assessment GlobeNewswire August 12, 2025 U.S. Patent No. 12379378-B2 protects biomarker-driven systems and methods to assess progression risk in Barrett's esophagus and esophageal adenocarcinoma; issuance follows the successful BE-Smart(TM) test validation (>95% technical success) and, together with BE-Smart's demonstrated compatibility

AIBotics, Inc. Issues Mid-Year Shareholder Update Highlighting Corporate Progress, Technology Development, and Strategic Roadmap for Agentic AI Integration

AIBotics, Inc. Issues Mid-Year Shareholder Update Highlighting Corporate Progress, Technology Development, and Strategic Roadmap for Agentic AI Integration AIBotics in negotiations for a pilot program with a China-based global leader in commercial service robots designed to interact with people and collaborate with other robots GlobeNewswire August 12, 2025 MIAMI, Aug. 12, 2025 (GLOBE NEWSWIRE) —

Scroll to Top